ZA201300012B - Synthesis and use of kinase inhibitors - Google Patents

Synthesis and use of kinase inhibitors

Info

Publication number
ZA201300012B
ZA201300012B ZA2013/00012A ZA201300012A ZA201300012B ZA 201300012 B ZA201300012 B ZA 201300012B ZA 2013/00012 A ZA2013/00012 A ZA 2013/00012A ZA 201300012 A ZA201300012 A ZA 201300012A ZA 201300012 B ZA201300012 B ZA 201300012B
Authority
ZA
South Africa
Prior art keywords
synthesis
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
ZA2013/00012A
Other languages
English (en)
Inventor
Yixiong Lei
Carl Henry Behrens
Hui Yin Li
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of ZA201300012B publication Critical patent/ZA201300012B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ZA2013/00012A 2010-06-30 2013-01-02 Synthesis and use of kinase inhibitors ZA201300012B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35994210P 2010-06-30 2010-06-30
PCT/US2011/042169 WO2012012139A1 (en) 2010-06-30 2011-06-28 Synthesis and use of kinase inhibitors

Publications (1)

Publication Number Publication Date
ZA201300012B true ZA201300012B (en) 2013-09-25

Family

ID=45497129

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/00012A ZA201300012B (en) 2010-06-30 2013-01-02 Synthesis and use of kinase inhibitors

Country Status (10)

Country Link
US (1) US9505719B2 (enExample)
EP (1) EP2588476A4 (enExample)
JP (1) JP5923499B2 (enExample)
CN (1) CN103168037A (enExample)
AU (1) AU2011280031B2 (enExample)
CA (1) CA2803005A1 (enExample)
MX (1) MX343894B (enExample)
NZ (1) NZ604801A (enExample)
WO (1) WO2012012139A1 (enExample)
ZA (1) ZA201300012B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) * 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU1167702A (en) 2000-10-11 2002-04-22 Cephalon Inc Compositions comprising modafinil compounds
TW200409629A (en) * 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
US20080119515A1 (en) 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
CN101119976B (zh) 2005-02-18 2010-12-22 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯氨基)嘧啶氧化物衍生物
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
JP5592647B2 (ja) * 2006-04-28 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション 制御された析出による6,6−ジメチル−3−アザ−ビシクロ[3.1.0]ヘキサン−アミド化合物の析出および単離のための方法、ならびにこれを含む医薬処方物
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
PT2046292E (pt) 2006-07-21 2010-04-26 Novartis Ag Formulações de éteres benzimidazolil-piridílicos
CN103588704B (zh) * 2007-03-16 2016-09-14 斯克里普斯研究学院 粘着斑激酶抑制剂
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
US8569298B2 (en) * 2008-06-17 2013-10-29 Astrazeneca Ab Pyridine compounds
CN102648197A (zh) 2009-08-12 2012-08-22 铂雅制药公司 促进细胞凋亡和抑制转移的方法
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
JP5923499B2 (ja) 2016-05-24
NZ604801A (en) 2015-03-27
WO2012012139A1 (en) 2012-01-26
EP2588476A4 (en) 2014-07-23
CA2803005A1 (en) 2012-01-26
MX343894B (es) 2016-11-28
EP2588476A1 (en) 2013-05-08
JP2013529687A (ja) 2013-07-22
US20140235635A1 (en) 2014-08-21
US9505719B2 (en) 2016-11-29
CN103168037A (zh) 2013-06-19
AU2011280031B2 (en) 2015-09-10
AU2011280031A1 (en) 2013-01-10
MX2012014986A (es) 2013-07-03

Similar Documents

Publication Publication Date Title
IL266168A (en) Heteroaryl compounds and methods of their use
EP2776837A4 (en) COMBINATION OF KINASEINHIBITORS AND THEIR USE
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
ZA201100211B (en) Kinase inhibitors and methods of use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
AP3210A (en) Pyrazolyt quinazoline kinase inhibitors
ZA201208373B (en) Compounds useful as inhibitors of atr kinase
SG10201405568UA (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
IL221311A0 (en) Inhibitors of protein kinases
IL222291A0 (en) Compositions and methods of synthesis of pyridinoylpiperidine
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
ZA201206456B (en) Uses of dgati inhibitors
IL225605A0 (en) Polo-like kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
IL257429B (en) d2 antagonists, methods of synthesis and methods of use
PL3254669T3 (pl) Kosmetyczne zastosowanie N-podstawionych sulfonyloksybenzyloamin i związków powiązanych
IL220187A0 (en) Inhibitors of sphingosine kinase
IL226005A0 (en) Inhibitors of cell death and uses thereof
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
ZA201300012B (en) Synthesis and use of kinase inhibitors
EP2603459A4 (en) SYNTHESIS OF STANNAN AND DEUTEROSTANNAN
ZA201300009B (en) Oral formulation of kinase inhibitors
IL225708A0 (en) Methods for the synthesis of scylitol and related compounds